

**Global Bridges at Mayo Clinic and Pfizer Global Medical Grants
Request For Proposals (RFP)
Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis**

Background and Purpose of this RFP	<p>Amyloidosis is often misdiagnosed. For example, it is estimated that the correct diagnosis of TTR amyloidosis is delayed by years, in part because it is a multisystemic disorder. Our goal is to help accelerate this patient journey by supporting capacity building programs.</p> <p>We aim to raise awareness and close knowledge gaps to reduce the time it takes for patients to be correctly diagnosed and make treatment more accessible, while supporting the development of a global network of TTR amyloidosis experts. Expanding the community of practice will help decrease the distance patients need to travel to be diagnosed, although valuable guidance may still be obtained from experienced centers further from home.</p>
Geographic Scope	Global
Application process	<p>This application process has two steps: Letters of Intent (LOIs) and Full Proposals. The application process and format for LOIs is described below. Based on an expert panel review of LOIs, a number of applicants will be invited to submit Full Proposals.</p>
Funding and Administration of Projects	<p>Projects selected for funding will be funded directly by Pfizer Inc.</p> <p>Operational and technical support for funded projects will be provided by Mayo Clinic.</p>
Applicant Eligibility	<p>Applications are invited from institutions, organizations or associations, e.g. professional schools, hospitals, healthcare systems, universities, patient advocacy groups, professional associations, government agencies</p> <p>Grants can only be awarded to organizations, not individuals or medical practice groups.</p>
Clinical Area	TTR Amyloidosis (any organ system)
Characteristics of a Successful Proposal	<p>In order to increase the capacity of the health care system to provide more timely diagnosis and appropriate treatment to TTR amyloidosis sufferers in any organ, we are interested in receiving proposals that:</p> <ul style="list-style-type: none"> • Reduce the time to correct diagnosis, among a broad audience of health care professionals, including increasing coordination across specialties; AND • Build on evidence and international best practice; AND • Include a robust and well-defined plan for evaluation and dissemination; AND

	<ul style="list-style-type: none"> • Support the development of a global network of health care professionals capable of diagnosing and treating TTR amyloidosis, AND • support the development of a global network of TTR amyloidosis experts • Include a plan to sustain the project beyond the period of funding.
Out of Scope of this Call	It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
Funding Available/Maximum Award Levels	Total funding available for this RFP is US \$1,000,000. We anticipate funding between 5 - 8 projects; additional guidance regarding funding may be provided to applicants following review of LOIs.
How to Submit	<ol style="list-style-type: none"> 1. Please go to www.cybergrants.com/pfizer/loi and sign in. First-time users should click "Create your password". 2. Select the following Primary Area of Interest: TTR Amyloidosis 3. Select the following Competitive Grant Program Name: 2020 RD G - Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis 4. Complete all required sections of the online application. See Appendix A for details.
Timing	<p>LOIs must be completed in the CyberGrants system no later than 5:00pm New York time on Thursday, 7 May 2020 [Deadline Extended].</p> <p>All applicants will be notified of the outcome of their application by email in early June. Applicants may also be contacted to provide further clarification in order to support the review of this application.</p> <p>Anticipated project start date for funded projects is early 2021.</p>
Questions	If you have any questions regarding this RFP, please direct them in writing to Katie Kemper at Global Bridges (kemper.katherine@mayo.edu) or the Pfizer Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com).

**** OVERVIEW OF LOI APPLICATION ON FOLLOWING PAGES****

Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis LOI Overview

The Letter of Intent (LOI) will be accepted via an online application. An outline of the application elements is provided below.

Goals and Objectives	<i>Briefly state the overall goal and objectives of the proposed project</i>
Assessment of Need for the Project	<i>Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data were analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.</i>
Target Audience	<i>Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.</i>
Project Design and Methods	<i>Outline the proposed methodology and key stages or milestones of your planned approach. Maximum project length is two years.</i>
Innovation	<ul style="list-style-type: none"> • <i>Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.</i> • <i>Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.</i>
Evaluation and Outcomes	<p><i>Describe how you will measure the success of your project. What measures and metrics will you use to evaluate the impact of the project? Describe your plan to capture baseline and end-of-project metrics and results. <u>Example</u> metrics include:</i></p> <ul style="list-style-type: none"> • <i>Number of health care professionals trained</i> • <i>Number of patients diagnosed with TTR Amyloidosis</i> • <i>Number of patients receiving intervention</i>

Anticipated Project Timeline	<i>Provide an anticipated timeline for your project including project start/end dates</i>
Additional Information	<i>Educational Sustainability: How will the results of the project be shared? How will the project support ongoing improvement in amyloidosis treatment and training?</i>
Organizational Detail	<i>Describe the mission, capability, and relevant previous activity of the applicant organization and how it will facilitate the project. Also include information about collaborating or project-partner organizations as applicable.</i>
Monetary Request	<p><i>Please indicate total monetary amount being requested for this project in United States Dollars (USD). A full budget is not required for this Letter of Intent and is requested only at the Full Proposal stage.</i></p> <p>While estimating your budget please keep the following items in mind:</p> <ul style="list-style-type: none"> ○ Institutional overhead and indirect costs may be included within the grant request. Examples include human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance as well as additional project expenses such as costs for publication, IRB / IEC review fees, software license fees, and travel. Please note: Pfizer does not provide funding for capital equipment. ○ Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects ○ It should be noted that grants awarded through GMG cannot be used to purchase therapeutic agents (prescription or non-prescription).